SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing extreme volatility, with the community actively debating whether it's a short squeeze or a pump and dump. The stock's low float and history of reverse splits are fueling speculation, with some comparing it to previous high-flying stocks like HKD and TGL. Traders are closely watching for offering news and momentum above key price levels, while others are suggesting it's overvalued and due for a correction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending amid speculation of acquiring Warner Bros. Discovery, potentially creating a streaming giant with HBO content; the community debates the deal's implications, regulatory hurdles, and whether it's a strategic win or overreach. Community sentiment seems mixed, with some anticipating a significant boost if the acquisition is approved, while others express concerns regarding regulatory hurdles and market saturation.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TGL is trending due to a recent reverse split and resulting small float, leading to high volatility and discussions of potential short squeezes. The community is comparing TGL to other high-flying stocks like $SMX, with some anticipating a similar explosive run. Bullish sentiment is fueled by the company's shift towards fintech and AI, with potential catalysts including new product rollouts and partnership announcements.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending due to increased social media and community attention, with traders actively discussing a potential short squeeze and comparing it to recent runs of other low float stocks. The stock's high short interest and cost to borrow are key talking points, with some believing it has the potential for significant upward movement. However, caution is advised due to the company's history of reverse splits and volatile price action.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Traders are actively discussing Adobe's ($ADBE) recent performance, with some citing technical indicators suggesting a bullish trend, while others express frustration with the stock's inability to sustain gains. Community sentiment appears mixed amidst discussions around AI competition, potential undervaluation, and upcoming earnings. Chatter includes opinions on management, potential acquisitions, and speculation on future price movements.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices have been volatile, with traders actively discussing potential entry points and swing trading strategies. Community members are weighing factors like weather forecasts, storage levels, and technical indicators to gauge short-term movements. Some traders express caution, citing the potential for price manipulation and the impact of contract rollovers.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid speculation of a short squeeze, fueled by investor Martin Shkreli's bullish stance and a $100 near-term price target. The community is actively discussing the company's potential in photonics and comparing it to recent high-flying stocks like $SMX. With high volume and rising interest, traders are closely watching for continued upward momentum.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending amid speculation of a potential acquisition by Netflix, sparking debates about the deal's value and regulatory hurdles. Community chatter revolves around competing bids from Paramount and Comcast, with some expressing concerns over potential market manipulation and the fairness of the bidding process. Discussions also include the potential impact on streaming competition and the future of WBD's assets.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne ($S) is trending following earnings, with community members noting the raised revenue forecast and discussing whether the stock is undervalued compared to its peers in the cybersecurity sector like Crowdstrike.  Some are focused on potential buyout scenarios and upcoming price target adjustments from analysts. There's also discussion around CFO departure and potential impact.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors debate its valuation after Q3 earnings and revenue beat estimates. While subscription growth is fueling positive sentiment and multiple analysts upgraded the stock, some community members point to negative cash flow and strong resistance around the $90 mark. Discussions also include potential catalysts from AI and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What is HC Wainwright's Estimate for Ocugen FY2025 Earnings?

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Ocugen in a research note issued on Thursday, November 6th. HC Wainwright...

Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. $OCGN

Y Intercept Hong Kong Ltd purchased a new stake in shares of Ocugen, Inc. (NASDAQ:OCGN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange...

Ocugen (NASDAQ:OCGN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Ocugen (NASDAQ:OCGN - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The firm...

Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -16.67% and +46.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know

Ocugen (OCGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Shares of Ocugen, Inc. (OCGN) rose 3% on Friday morning after the company reported a better-than-feared first-quarter (Q1) loss.The biotechnology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-first-quarter-2025-financial">reported</a> a revenue of $1.5 million, up from $1 million in the corresponding quarter of 2024.Loss per share came in at $0.05, unchanged from the corresponding quarter of 2024, and better than the estimated loss of $0.06 per share.The company, which is developing gene therapies for blindness diseases, ended the quarter with cash and restricted cash totaling $38.1 million, compared to $58.8 million as of Dec. 31, 2024. It expects this will provide runway into the first quarter of 2026.CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the U.S. Food and Drug Administration (FDA) requesting approval for the distribution of three of its products in the next three years.“We remain steadfast in our mission to provide a one-time therapy for life to address considerable unmet medical needs that exist for millions of patients facing the terrifying prospect of losing their vision," he said.On Stocktwits, retail sentiment around Ocugen jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume stayed at high levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_9_57_35_AM_png_0d026d6926.webp" alt="Screenshot 2025-05-09 at 9.57.35 AM.png" width="630" height="63"><figcaption>OCGN's Sentiment Meter and Message Volume as of 9:24 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism for the stock, citing the three upcoming FDA applications.<stembedurl>https://stocktwits.com/FannyChmelar/message/614075330</stembedurl>Another noted that the low cash reserve is expected in a company not selling products yet.<stembedurl>https://stocktwits.com/Slapshot22/message/614070848</stembedurl><a href="https://stocktwits.com/symbol/OCGN">OCGN stock</a> is down by 21% this year and 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-faces-moltiply-lawsuit/chiWtc6RblO">Google Faces $3.3B Lawsuit From Italy’s Moltiply Group: Search Giant Disagrees With ‘Exorbitant’ Private Damages Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.

Equity

CEO Shankar Musunuri said that the company is “on track” to meet its goal of submitting applications to the FDA requesting approval for the distribution of three of its products in the next three years.


Ocugen, Inc.'s stock dropped 2.8% during Wednesday's session but bounced back in extended trading after the company posted a quarterly earnings report that exceeded revenue expectations.The biopharmaceutical company, which focuses on developing gene therapies for eye diseases, reported a fourth-quarter loss of $0.05 per share, in line with estimates.&nbsp;Revenue was $764,000, down from $1.4 million a year ago due to reduced co-development services, but still well above the $400,000 analysts expected.Ocugen's modifier gene therapy platform includes OCU400, OCU410, and OCU410ST, which target inherited retinal diseases (IRDs) and conditions like dry age-related macular degeneration (dAMD) and Stargardt disease.Its OCU400 is in Phase 3 clinical trials for retinitis pigmentosa (RP) in the U.S. and Canada, with enrollment expected to be completed in the first half of 2025.OCU500, Ocugen's inhaled mucosal COVID-19 vaccine, recently received FDA clearance for an Investigational New Drug (IND) application.&nbsp;The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor a Phase 1 trial evaluating two delivery routes — lung inhalation and nasal spray.To extend its cash runway into the first quarter of 2026 and support ongoing clinical trials, Ocugen secured $65 million in equity and debt financing in the second half of 2024.&nbsp;In May, the company was included in the Russell Index.On Stocktwits, sentiment for Ocugen ended Wednesday higher within the 'bullish' zone, with message volume surging 32%.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCGN_sentiment_and_message_volume_as_of_March_5_42ff8160da.png" alt="OCGN sentiment and message volume as of March 5.png" width="1316" height="302"><figcaption>OCGN sentiment and message volume as of March 5 | source: Stocktwits</figcaption></figure>One retail trader said the value of Ocugen's pipeline "is insane and I'll be holding when it comes to fruition."<stembedurl>https://stocktwits.com/SGimvesting/message/606846472</stembedurl>Another was hopeful after pointing out that CEO Shankar Musunuri confirmed NIAID's funding support for OCU500's Phase 1 trial next quarter.<stembedurl>https://stocktwits.com/Hamiltoes/message/606856276</stembedurl>Ocugen's ambitious roadmap targets three potential Biologics License Applications (BLAs) between 2026 and 2028, covering RP, Stargardt, and geographic atrophy (GA).However, Ocugen faces a significant short interest rate of 20.7%, according to Koyfin data.&nbsp;The stock trades 1,033% below the average analyst price target of $6.50, with two analysts rating it a 'buy' and two a 'strong buy.'Shares of Ocugen are down over 33% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates

Watchers on Stocktwits expressed optimism about the company’s pipeline and its aim to secure three BLAs over the next three years.

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Kaskela Law LLC announces that it is investigating Ocugen, Inc. (NASDAQ: OCGN) on behalf of the companys shareholders. Since July 2024, shares of Ocugens stock have declined in value from a trading...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ocugen Inc

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.06	--	--	N/A
Q3 '25	-$0.06	-$0.07	-25.00%	MISSED
Q2 '25	-$0.06	-$0.05	10.71%	BEAT
Q1 '25	-$0.06	-$0.05	13.04%	BEAT
Q4 '24	-$0.05	-$0.05	6.25%	BEAT

OCGN
Ocugen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest OCGN News

OCGNOcugen Inc